{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,20]],"date-time":"2026-11-20T19:05:42Z","timestamp":1795201542192,"version":"4.10.3"},"reference-count":26,"publisher":"Oxford University Press (OUP)","issue":"31","license":[{"start":{"date-parts":[[2020,3,28]],"date-time":"2020-03-28T00:00:00Z","timestamp":1585353600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/academic.oup.com\/journals\/pages\/open_access\/funder_policies\/chorus\/standard_publication_model"}],"funder":[{"DOI":"10.13039\/100000050","name":"National Heart Lung and Blood Institute","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100000050","name":"NHLBI","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000050","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"NIH","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2020,8,14]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec>\n                  <jats:title>Aims<\/jats:title>\n                  <jats:p>In epidemiologic cohorts initiated &amp;gt;30\u2009years ago, inflammatory biomarkers, such as interleukin-6 (IL-6) and high-sensitivity C-reactive protein (hsCRP) were shown to independently predict future cardiovascular events with a magnitude of effect comparable to that of low-density lipoprotein cholesterol (LDLC). Whether aggressive contemporary therapy for atherosclerosis has altered these relationships is unknown yet has major implications for future drug development.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Methods and results<\/jats:title>\n                  <jats:p>Interleukin-6, hsCRP, and LDLC were measured at baseline in up to 4168 North American patients enrolled in the contemporary Cardiovascular Inflammation Reduction Trial with prior myocardial infarction or multivessel coronary disease who additionally had diabetes or metabolic syndrome and were followed for a period of up to 5\u2009years for incident major recurrent cardiovascular events and all-cause mortality. Three-quarters of the cohort were previously revascularized and the great majority was taking statins, angiotensin blocking agents, beta-blockers, and antithrombotic agents. Participants were randomly allocated to low-dose methotrexate 15\u2009mg weekly or to placebo. Randomized use of methotrexate had no effect on event rates nor plasma levels of IL-6, hsCRP, or LDL over time. Yet, baseline levels of IL-6, hsCRP, and LDLC were all predictors of major recurrent cardiovascular events; adjusted hazard ratios [HR; 95% confidence interval (CI)] for the lowest to highest baseline quartiles of IL-6 were 1.0 (referent), 1.66 (1.18\u20132.35), 1.92 (1.36\u20132.70), and 2.11 (1.49\u20132.99; P\u2009&amp;lt;\u20090.0001), while adjusted HRs for increasing quartiles of hsCRP were 1.0 (referent), 1.28 (0.92\u20131.79), 1.73 (1.25\u20132.38), and 1.79 (1.28\u20132.50; P\u2009&amp;lt;\u20090.0001) and adjusted HRs for increasing quartiles of LDLC were 1.0 (referent), 1.12 (0.78\u20131.62), 1.25 (0.87\u20131.79), and 2.38 (1.72\u20133.30; P\u2009&amp;lt;\u20090.0001). Effect estimates were not statistically different in these analyses for comparisons between IL-6, hsCRP, or LDLC, although IL-6 was the strongest predictor of all-cause mortality. The highest absolute risks were observed among those with elevated levels of both cholesterol and inflammation [HR 6.4 (95% CI 2.9\u201314.1) for those in the top quartiles of baseline IL-6 and LDLC, HR 4.9 (95% CI 2.6\u20139.4) for those in the top quartiles of baseline hsCRP and LDLC, both P\u2009&amp;lt;\u20090.0001].<\/jats:p>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Conclusion<\/jats:title>\n                  <jats:p>Despite aggressive contemporary secondary prevention efforts, the relationships between inflammation, cholesterol, and cardiovascular risk are largely unchanged from those described two decades ago. These data are consistent with the hypothesis that future treatments for atherosclerosis may require a combination of inflammation inhibition and additional cholesterol reduction.<\/jats:p>\n                  <jats:p\/>\n               <\/jats:sec>\n               <jats:sec>\n                  <jats:title>Clinical trial<\/jats:title>\n                  <jats:p>ClinicalTrials.gov NCT01594333.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1093\/eurheartj\/ehaa160","type":"journal-article","created":{"date-parts":[[2020,3,2]],"date-time":"2020-03-02T20:19:27Z","timestamp":1583180367000},"page":"2952-2961","source":"Crossref","is-referenced-by-count":154,"title":["Comparison of interleukin-6, C-reactive protein, and low-density lipoprotein cholesterol as biomarkers of residual risk in contemporary practice: secondary analyses from the Cardiovascular Inflammation Reduction Trial"],"prefix":"10.1093","volume":"41","author":[{"given":"Paul M","family":"Ridker","sequence":"first","affiliation":[{"name":"Division of Preventive Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School , 900 Commonwealth Avenue, Brigham and Women\u2019s Hospital, Boston, MA 02215, USA"},{"name":"Cardiovascular Division, Brigham and Women\u2019s Hospital , 75 Francis Street, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean G","family":"MacFadyen","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School , 900 Commonwealth Avenue, Brigham and Women\u2019s Hospital, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert J","family":"Glynn","sequence":"additional","affiliation":[{"name":"Division of Preventive Medicine, Center for Cardiovascular Disease Prevention, Brigham and Women\u2019s Hospital, Harvard Medical School , 900 Commonwealth Avenue, Brigham and Women\u2019s Hospital, Boston, MA 02215, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary","family":"Bradwin","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Boston Children\u2019s Hospital , 300 Longwood Avenue, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed A","family":"Hasan","sequence":"additional","affiliation":[{"name":"National Heart Lung and Blood Institute , 9000 Rockville Pike, Bethesda, MD 20892, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nader","family":"Rifai","sequence":"additional","affiliation":[{"name":"Department of Laboratory Medicine, Boston Children\u2019s Hospital , 300 Longwood Avenue, Boston, MA 02115, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"286","published-online":{"date-parts":[[2020,3,28]]},"reference":[{"key":"2022102507121323200_ehaa160-B1","doi-asserted-by":"crossref","first-page":"973","DOI":"10.1056\/NEJM199704033361401","article-title":"Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men","volume":"336","author":"Ridker","year":"1997","journal-title":"N Engl J Med"},{"key":"2022102507121323200_ehaa160-B2","doi-asserted-by":"crossref","first-page":"836","DOI":"10.1056\/NEJM200003233421202","article-title":"C-reactive protein and other markers of inflammation in the prediction of cardiovascular disease in women","volume":"342","author":"Ridker","year":"2000","journal-title":"N Engl J Med"},{"key":"2022102507121323200_ehaa160-B3","doi-asserted-by":"crossref","first-page":"1767","DOI":"10.1161\/01.CIR.101.15.1767","article-title":"Plasma concentration of interleukin-6 and the risk of future myocardial infarction among apparently healthy men","volume":"101","author":"Ridker","year":"2000","journal-title":"Circulation"},{"key":"2022102507121323200_ehaa160-B4","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/S0140-6736(09)61717-7","article-title":"Emerging Risk Factors Collaboration. C-reactive protein concentration and risk of coronary heart disease, stroke, and mortality: an individual participant meta-analysis","volume":"375","year":"2010","journal-title":"Lancet"},{"key":"2022102507121323200_ehaa160-B5","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1093\/eurheartj\/eht367","article-title":"Inflammatory cytokines and risk of coronary heart disease: new prospective study and updated meta-analysis","volume":"35","author":"Kaptoge","year":"2014","journal-title":"Eur Heart J"},{"key":"2022102507121323200_ehaa160-B6","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/j.jacc.2015.11.037","article-title":"A test in context: high-sensitivity C-reactive protein","volume":"67","author":"Ridker","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"2022102507121323200_ehaa160-B7","doi-asserted-by":"crossref","first-page":"213","DOI":"10.1016\/j.ijcard.2018.02.062","article-title":"All roads lead to IL-6: a central hub of cardiometabolic signaling","volume":"259","author":"Libby","year":"2018","journal-title":"Int J Cardiol"},{"key":"2022102507121323200_ehaa160-B8","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1161\/CIRCRESAHA.115.306656","article-title":"From C-reactive protein to interleukin-6 to interleukin-1: moving upstream to identify novel targets for atheroprotection","volume":"118","author":"Ridker","year":"2016","journal-title":"Circ Res"},{"key":"2022102507121323200_ehaa160-B9","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1016\/S0140-6736(11)61931-4","article-title":"Interleukin-6 receptor pathways in coronary heart disease: a collaborative meta-analysis of 82 studies","volume":"379","author":"Sarwar","year":"2012","journal-title":"Lancet"},{"key":"2022102507121323200_ehaa160-B10","doi-asserted-by":"crossref","first-page":"1214","DOI":"10.1016\/S0140-6736(12)60110-X","article-title":"The interleukin-6 receptor as a target for prevention of coronary heart disease: a Mendelian randomisation analysis","volume":"379","author":"Swerdlow","year":"2012","journal-title":"Lancet"},{"key":"2022102507121323200_ehaa160-B11","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1056\/NEJMoa1707914","article-title":"Antiinflammatory therapy with canakinumab for atherosclerotic disease","volume":"377","author":"Ridker","year":"2017","journal-title":"N Engl J Med"},{"key":"2022102507121323200_ehaa160-B12","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1016\/S0140-6736(17)32814-3","article-title":"Relationship of C-reactive protein reduction to cardiovascular event reduction following treatment with canakinumab: a secondary analysis from the CANTOS randomized controlled trial","volume":"391","author":"Ridker","year":"2018","journal-title":"Lancet"},{"key":"2022102507121323200_ehaa160-B13","doi-asserted-by":"crossref","first-page":"3499","DOI":"10.1093\/eurheartj\/ehy310","article-title":"Modulation of the interleukin-6 signaling pathway and incidence rates of atherosclerotic events and all-cause mortality: analyses from the Canakinumab Anti-inflammatory Thrombosis Outcomes Study (CANTOS)","volume":"39","author":"Ridker","year":"2018","journal-title":"Eur Heart J"},{"key":"2022102507121323200_ehaa160-B14","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/j.jacc.2018.12.083","article-title":"Targeting the immune system in atherosclerosis. JACC state-of-the art review","volume":"73","author":"Zhao","year":"2019","journal-title":"J Am Coll Cardiol"},{"key":"2022102507121323200_ehaa160-B15","doi-asserted-by":"crossref","DOI":"10.1093\/eurheartj\/ehz283","article-title":"Immunotherapy for cardiovascular disease","volume":"40","author":"Lutgens","year":"2019","journal-title":"Eur Heart J"},{"key":"2022102507121323200_ehaa160-B16","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1161\/CIRCRESAHA.118.313129","article-title":"Anticytokine agents. Targeting interleukin signaling pathways for the treatment of athererothrombosis","volume":"124","author":"Ridker","year":"2019","journal-title":"Circ Res"},{"key":"2022102507121323200_ehaa160-B17","doi-asserted-by":"crossref","first-page":"2406","DOI":"10.1093\/eurheartj\/ehw171","article-title":"Effect of a single dose of the interleukin-6 receptor antagonist tocilizumab on inflammation and troponin T release in patients with non-ST-elevation myocardial infarction: a double-blind, randomized, placebo-controlled phase 2 trial","volume":"37","author":"Kleveland","year":"2016","journal-title":"Eur Heart J"},{"key":"2022102507121323200_ehaa160-B18","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1056\/NEJMoa1912388","article-title":"Efficacy and safety of low-dose colchicine after myocardial infarction","volume":"381","author":"Tardif","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102507121323200_ehaa160-B19","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1001\/jama.286.1.64","article-title":"Ridker PM; PRINCE Investigators. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation\/CRP evaluation (PRINCE): a randomized trial and cohort study","volume":"286","author":"Albert","year":"2001","journal-title":"JAMA"},{"key":"2022102507121323200_ehaa160-B20","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1056\/NEJMoa1809798","article-title":"Low-dose methotrexate for the prevention of atherosclerotic events","volume":"380","author":"Ridker","year":"2019","journal-title":"N Engl J Med"},{"key":"2022102507121323200_ehaa160-B21","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1161\/CIRCULATIONAHA.118.034032","article-title":"Inflammatory and cholesterol risk in the FOURIER trial (Further cardiovascular outcomes research with PCSK9 inhibition in patients with elevated risk)","volume":"138","author":"Bohula","year":"2018","journal-title":"Circulation"},{"key":"2022102507121323200_ehaa160-B22","doi-asserted-by":"crossref","first-page":"141","DOI":"10.1161\/CIRCULATIONAHA.118.034645","article-title":"Residual inflammatory risk on treatment with PCSK9 inhibition and statin therapy","volume":"138","author":"Pradhan","year":"2018","journal-title":"Circulation"},{"key":"2022102507121323200_ehaa160-B23","doi-asserted-by":"crossref","first-page":"3320","DOI":"10.1016\/j.jacc.2018.06.082","article-title":"Clinician\u2019s guide to reducing inflammation to reduce atherothrombotic risk: JACC review topic of the week","volume":"72","author":"Ridker","year":"2018","journal-title":"J Am Coll Cardiol"},{"key":"2022102507121323200_ehaa160-B24","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1093\/cvr\/cvy293","article-title":"Identifying the anti-inflammatory response to lipid lowering therapy: a position paper from the working group on atherosclerosis and vascular biology of the European society of cardiology","volume":"115","author":"Tunon","year":"2019","journal-title":"Cardiovasc Res"},{"key":"2022102507121323200_ehaa160-B25","doi-asserted-by":"crossref","first-page":"e005077","DOI":"10.1161\/JAHA.116.005077","article-title":"Inflammatory biomarkers interleukin-6 and c-reactive protein and outcomes in stable coronary heart disease: experiences from the stability (Stabilization of Atherosclerotic Plaque by Initiation of Darapladib Therapy) trial","volume":"6","author":"Held","year":"2017","journal-title":"J Am Heart Assoc"},{"key":"2022102507121323200_ehaa160-B26","doi-asserted-by":"crossref","first-page":"e005637","DOI":"10.1161\/JAHA.117.005637","article-title":"Interleukin-6 and the risk of adverse outcomes in patients after an acute coronary syndrome: observations from the SOLID-TIMI 52 (Stabilization of Plaque Using Darapladib-Thrombolysis in Myocardial Infarction 52) trial","volume":"6","author":"Fanola","year":"2017","journal-title":"J Am Heart Assoc"}],"container-title":["European Heart Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/31\/2952\/46616721\/eurheartj_41_31_2952.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/academic.oup.com\/eurheartj\/article-pdf\/41\/31\/2952\/46616721\/eurheartj_41_31_2952.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,25]],"date-time":"2022-10-25T07:12:52Z","timestamp":1666681972000},"score":1,"resource":{"primary":{"URL":"https:\/\/academic.oup.com\/eurheartj\/article\/41\/31\/2952\/5813080"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,3,28]]},"references-count":26,"journal-issue":{"issue":"31","published-online":{"date-parts":[[2020,3,28]]},"published-print":{"date-parts":[[2020,8,14]]}},"URL":"https:\/\/doi.org\/10.1093\/eurheartj\/ehaa160","relation":{},"ISSN":["0195-668X","1522-9645"],"issn-type":[{"value":"0195-668X","type":"print"},{"value":"1522-9645","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2020,8,14]]},"published":{"date-parts":[[2020,3,28]]}}}